Influence of HIV infection on the natural history of hepatocellular carcinoma: Results from a global multicohort study

and the Liver Cancer in HIV and ITA.LI.CA Study Groups

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

PURPOSE Conflicting evidence indicates that HIV seropositivity may influence the outcome of patients with hepatocellular carcinoma (HCC), a leading cause of mortality in people with HIV. We aimed to verify whether HIV affected the overall survival (OS) of patients with HCC, independent of treatment and geographic origin. PATIENTS AND METHODS We designed an international multicohort study of patients with HCC accrued from four continents who did not receive any anticancer treatment. We estimated the effect of HIV seropositivity on patients’ OS while accounting for common prognostic factors and demographic characteristics in uni- and multivariable models. RESULTS A total of 1,588 patients were recruited, 132 of whom were HIV positive. Most patients clustered within Barcelona Clinic Liver Cancer (BCLC) C or D criteria (n = 1,168 [74%]) and Child-Turcotte-Pugh (CTP) class B (median score, 7; interquartile range [IQR], 3). At HCC diagnosis, the majority of patients who were HIV-positive (n = 65 [64%]) had been on antiretrovirals for a median duration of 8.3 years (IQR, 8.59 years) and had median CD4 + cell counts of 256 (IQR, 284) with undetectable HIV RNA (n = 68 [52%]). OS decreased significantly throughout BCLC stages 0 to D (16, 12, 7.5, 3.1, and 3 months, respectively; P, .001). Median OS of patients who were HIV-positive was one half that of their HIV-uninfected counterparts (2.2 months [bootstrap 95% CI, 1.2 to 3.1 months] v 4.1 months [95% CI, 3.6 to 4.4 months]). In adjusted analyses, HIV seropositivity increased the hazard of death by 24% (P = .0333) independent of BCLC (P, .0001), CTP (P, .0001), a-fetoprotein (P, .0001), geographical origin (P, .0001), and male sex (P = .0016). Predictors of worse OS in patients who were HIV-positive included CTP (P = .0071) and a-fetoprotein (P, .0001). CONCLUSION Despite adequate antiretroviral treatment, HIV seropositivity is associated with decreased survival in HCC, independent of stage, anticancer treatment, and geographical origin. Mechanistic studies investigating the immunobiology of HIV-associated HCC are urgently required.

Original languageEnglish (US)
Pages (from-to)296-304
Number of pages9
JournalJournal of Clinical Oncology
Volume37
Issue number4
DOIs
StatePublished - Feb 1 2019

Fingerprint

HIV Infections
Hepatocellular Carcinoma
HIV
HIV Seropositivity
Survival
Liver Neoplasms
Fetal Proteins
Therapeutics
CD4 Lymphocyte Count
Demography
RNA
Mortality

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Influence of HIV infection on the natural history of hepatocellular carcinoma : Results from a global multicohort study. / and the Liver Cancer in HIV and ITA.LI.CA Study Groups.

In: Journal of Clinical Oncology, Vol. 37, No. 4, 01.02.2019, p. 296-304.

Research output: Contribution to journalArticle

and the Liver Cancer in HIV and ITA.LI.CA Study Groups. / Influence of HIV infection on the natural history of hepatocellular carcinoma : Results from a global multicohort study. In: Journal of Clinical Oncology. 2019 ; Vol. 37, No. 4. pp. 296-304.
@article{60e5e288082947e9b8986e153976be0f,
title = "Influence of HIV infection on the natural history of hepatocellular carcinoma: Results from a global multicohort study",
abstract = "PURPOSE Conflicting evidence indicates that HIV seropositivity may influence the outcome of patients with hepatocellular carcinoma (HCC), a leading cause of mortality in people with HIV. We aimed to verify whether HIV affected the overall survival (OS) of patients with HCC, independent of treatment and geographic origin. PATIENTS AND METHODS We designed an international multicohort study of patients with HCC accrued from four continents who did not receive any anticancer treatment. We estimated the effect of HIV seropositivity on patients’ OS while accounting for common prognostic factors and demographic characteristics in uni- and multivariable models. RESULTS A total of 1,588 patients were recruited, 132 of whom were HIV positive. Most patients clustered within Barcelona Clinic Liver Cancer (BCLC) C or D criteria (n = 1,168 [74{\%}]) and Child-Turcotte-Pugh (CTP) class B (median score, 7; interquartile range [IQR], 3). At HCC diagnosis, the majority of patients who were HIV-positive (n = 65 [64{\%}]) had been on antiretrovirals for a median duration of 8.3 years (IQR, 8.59 years) and had median CD4 + cell counts of 256 (IQR, 284) with undetectable HIV RNA (n = 68 [52{\%}]). OS decreased significantly throughout BCLC stages 0 to D (16, 12, 7.5, 3.1, and 3 months, respectively; P, .001). Median OS of patients who were HIV-positive was one half that of their HIV-uninfected counterparts (2.2 months [bootstrap 95{\%} CI, 1.2 to 3.1 months] v 4.1 months [95{\%} CI, 3.6 to 4.4 months]). In adjusted analyses, HIV seropositivity increased the hazard of death by 24{\%} (P = .0333) independent of BCLC (P, .0001), CTP (P, .0001), a-fetoprotein (P, .0001), geographical origin (P, .0001), and male sex (P = .0016). Predictors of worse OS in patients who were HIV-positive included CTP (P = .0071) and a-fetoprotein (P, .0001). CONCLUSION Despite adequate antiretroviral treatment, HIV seropositivity is associated with decreased survival in HCC, independent of stage, anticancer treatment, and geographical origin. Mechanistic studies investigating the immunobiology of HIV-associated HCC are urgently required.",
author = "{and the Liver Cancer in HIV and ITA.LI.CA Study Groups} and Pinato, {David J.} and Elias Allara and Chen, {Ting Yi} and Franco Trevisani and Beatriz Minguez and Marco Zoli and Marianne Harris and Pria, {Alessia Dalla} and Nicol{\'a}s Merchante and Heather Platt and Mamta Jain and Eugenio Caturelli and Luciana Kikuchi and Juan Pineda and Mark Nelson and Fabio Farinati and Rapaccini, {Gian Ludovico} and Ayse Aytaman and Michael Yin and Tan, {Chee Kiat} and Mark Bower and Giannini, {Edoardo G.} and Norbert Br{\"a}u",
year = "2019",
month = "2",
day = "1",
doi = "10.1200/JCO.18.00885",
language = "English (US)",
volume = "37",
pages = "296--304",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Influence of HIV infection on the natural history of hepatocellular carcinoma

T2 - Results from a global multicohort study

AU - and the Liver Cancer in HIV and ITA.LI.CA Study Groups

AU - Pinato, David J.

AU - Allara, Elias

AU - Chen, Ting Yi

AU - Trevisani, Franco

AU - Minguez, Beatriz

AU - Zoli, Marco

AU - Harris, Marianne

AU - Pria, Alessia Dalla

AU - Merchante, Nicolás

AU - Platt, Heather

AU - Jain, Mamta

AU - Caturelli, Eugenio

AU - Kikuchi, Luciana

AU - Pineda, Juan

AU - Nelson, Mark

AU - Farinati, Fabio

AU - Rapaccini, Gian Ludovico

AU - Aytaman, Ayse

AU - Yin, Michael

AU - Tan, Chee Kiat

AU - Bower, Mark

AU - Giannini, Edoardo G.

AU - Bräu, Norbert

PY - 2019/2/1

Y1 - 2019/2/1

N2 - PURPOSE Conflicting evidence indicates that HIV seropositivity may influence the outcome of patients with hepatocellular carcinoma (HCC), a leading cause of mortality in people with HIV. We aimed to verify whether HIV affected the overall survival (OS) of patients with HCC, independent of treatment and geographic origin. PATIENTS AND METHODS We designed an international multicohort study of patients with HCC accrued from four continents who did not receive any anticancer treatment. We estimated the effect of HIV seropositivity on patients’ OS while accounting for common prognostic factors and demographic characteristics in uni- and multivariable models. RESULTS A total of 1,588 patients were recruited, 132 of whom were HIV positive. Most patients clustered within Barcelona Clinic Liver Cancer (BCLC) C or D criteria (n = 1,168 [74%]) and Child-Turcotte-Pugh (CTP) class B (median score, 7; interquartile range [IQR], 3). At HCC diagnosis, the majority of patients who were HIV-positive (n = 65 [64%]) had been on antiretrovirals for a median duration of 8.3 years (IQR, 8.59 years) and had median CD4 + cell counts of 256 (IQR, 284) with undetectable HIV RNA (n = 68 [52%]). OS decreased significantly throughout BCLC stages 0 to D (16, 12, 7.5, 3.1, and 3 months, respectively; P, .001). Median OS of patients who were HIV-positive was one half that of their HIV-uninfected counterparts (2.2 months [bootstrap 95% CI, 1.2 to 3.1 months] v 4.1 months [95% CI, 3.6 to 4.4 months]). In adjusted analyses, HIV seropositivity increased the hazard of death by 24% (P = .0333) independent of BCLC (P, .0001), CTP (P, .0001), a-fetoprotein (P, .0001), geographical origin (P, .0001), and male sex (P = .0016). Predictors of worse OS in patients who were HIV-positive included CTP (P = .0071) and a-fetoprotein (P, .0001). CONCLUSION Despite adequate antiretroviral treatment, HIV seropositivity is associated with decreased survival in HCC, independent of stage, anticancer treatment, and geographical origin. Mechanistic studies investigating the immunobiology of HIV-associated HCC are urgently required.

AB - PURPOSE Conflicting evidence indicates that HIV seropositivity may influence the outcome of patients with hepatocellular carcinoma (HCC), a leading cause of mortality in people with HIV. We aimed to verify whether HIV affected the overall survival (OS) of patients with HCC, independent of treatment and geographic origin. PATIENTS AND METHODS We designed an international multicohort study of patients with HCC accrued from four continents who did not receive any anticancer treatment. We estimated the effect of HIV seropositivity on patients’ OS while accounting for common prognostic factors and demographic characteristics in uni- and multivariable models. RESULTS A total of 1,588 patients were recruited, 132 of whom were HIV positive. Most patients clustered within Barcelona Clinic Liver Cancer (BCLC) C or D criteria (n = 1,168 [74%]) and Child-Turcotte-Pugh (CTP) class B (median score, 7; interquartile range [IQR], 3). At HCC diagnosis, the majority of patients who were HIV-positive (n = 65 [64%]) had been on antiretrovirals for a median duration of 8.3 years (IQR, 8.59 years) and had median CD4 + cell counts of 256 (IQR, 284) with undetectable HIV RNA (n = 68 [52%]). OS decreased significantly throughout BCLC stages 0 to D (16, 12, 7.5, 3.1, and 3 months, respectively; P, .001). Median OS of patients who were HIV-positive was one half that of their HIV-uninfected counterparts (2.2 months [bootstrap 95% CI, 1.2 to 3.1 months] v 4.1 months [95% CI, 3.6 to 4.4 months]). In adjusted analyses, HIV seropositivity increased the hazard of death by 24% (P = .0333) independent of BCLC (P, .0001), CTP (P, .0001), a-fetoprotein (P, .0001), geographical origin (P, .0001), and male sex (P = .0016). Predictors of worse OS in patients who were HIV-positive included CTP (P = .0071) and a-fetoprotein (P, .0001). CONCLUSION Despite adequate antiretroviral treatment, HIV seropositivity is associated with decreased survival in HCC, independent of stage, anticancer treatment, and geographical origin. Mechanistic studies investigating the immunobiology of HIV-associated HCC are urgently required.

UR - http://www.scopus.com/inward/record.url?scp=85060958574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060958574&partnerID=8YFLogxK

U2 - 10.1200/JCO.18.00885

DO - 10.1200/JCO.18.00885

M3 - Article

C2 - 30562130

AN - SCOPUS:85060958574

VL - 37

SP - 296

EP - 304

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -